A Phase 2 interventional study of Placebo and Belimumab 1 mg/kg in Arthritis, Rheumatoid, sponsored by Human Genome Sciences Inc.. Completed at 63 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-08-14.
Sponsored by Human Genome Sciences Inc. (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · GlaxoSmithKline.
Among the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline, this one is the 6th largest by enrollment of the 40 interventional ones that give a count, is the only one that started in 2003, is one of 17 in phase 2, and was the 2nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →1 of the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline is open now, in 9 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Argentina, Brazil, France and 6 more countries
Ages 18–70
By country, each count listing its studies:
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 19 · Phase 3 8
First in 2001; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 283 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 52 across the 40 interventional studies, 32 across the 3 observational. Of the 40 that completed or were terminated, 17 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Human Genome Sciences Inc., one of the names counted as GlaxoSmithKline. Under that name alone:
Human Genome Sciences Inc. is the lead sponsor of 23 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 44 studies in Arthritis, Rheumatoid by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with rheumatoid arthritis (RA).
The purpose of this study is to evaluate the safety and efficacy of three different doses of belimumab (1 mg/kg, 4 mg/kg, and 10 mg/kg), administered in addition to standard therapy, compared to placebo plus standard therapy in patients with RA. All patients were to be dosed on Days 0, 14, and 28, then every 28 days for the remainder of 24 weeks. Patients completing the 24-week period could enter a 24-week open-label extension; belimumab patients received the same dose or were switched to 10 mg/kg at the investigator's discretion and former placebo patients received belimumab 10 mg/kg.
Primary Inclusion Criteria:
Primary Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: Belimumab 1 mg/kg
Drug: Belimumab 4 mg/kg
Drug: Belimumab 10 mg/kg
Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
Drug page: Belimumab
Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
Also known as: LymphoStat-B®, BENLYSTA®
Drug page: Belimumab
Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
Also known as: LymphoStat-B®, BENLYSTA®
Drug page: Belimumab
Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
Also known as: LymphoStat-B®, BENLYSTA®
Percentage of Patients With ACR20 (American College of Rheumatology) Response at Week 24, Based on Erythrocyte Sedimentation Rate (ESR)
An ACR20 response is defined as having at least a 20% improvement in tender and swollen joints as well as a 20% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate \[ESR\]).
Time frame: Baseline, 24 weeks
Percentage of Patients With an ACR50 Response at Week 24, Based on ESR
An ACR50 response is defined as having at least a 50% improvement in tender and swollen joints as well as a 50% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate \[ESR\]).
Time frame: Baseline, 24 weeks
Percentage of Patients With an ACR70 Response at Week 24, Based on ESR
An ACR70 response is defined as having at least a 70% improvement in tender and swollen joints as well as a 70% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate \[ESR\]).
Time frame: Baseline, 24 weeks
Time to First ACR20 Response, Based on ESR
The time to first ACR20 response (based on ESR) is defined as the time from the first dose to the first visit at which a patient first exhibited an ACR20 response, which may or may not have been sustained through Week 24.
Time frame: 0 to 24 weeks
Time to First ACR50 Response, Based on ESR
Measure not posted because time to ACR50 response was unable to be determined due to the small number of patients achieving an ACR50 response in the study.
Time frame: 0 to 24 weeks
Time to First ACR70 Response, Based on ESR
Measure not posted because time to ACR70 response was unable to be determined due to the small number of patients achieving an ACR70 response in the study.
Time frame: 0 to 24 weeks
Mean Change in Disease Activity Score 28 (DAS28) at Week 24
DAS is a composite index of a patient's level of RA disease activity. DAS28 is an abbreviated version of DAS, using a subset of 28 joints in the assessment, calculated based on 4 variables: 1) number of tender joints out of a total of 28 joints, 2) number of swollen joints out of a total of 28 joints, 3) ESR, 4) patient's global assessment of disease activity based on a 100-mm visual analog scale. The calculation provides a number on a scale from 0 to 10 (\>5.1=active disease; \<3.2=well controlled disease; \<2.6=remission). Change from baseline \>1.2 = good response and ≤0.6 = non-response.
Time frame: Baseline, 24 weeks
Time to First DAS28 Response
DAS28 response is defined as the time from the first dose to the first time at which a patient exhibited a "good" or a "moderate" improvement in RA disease activity, based on DAS28 improvements compared to baseline. Good response was defined as \>1.2 change from baseline and DAS28 score ≤ 3.2. No response was defined as ≤ 0.6 change from baseline in DAS28 score or change between ≤ 1.2 and \> 0.6 with a DAS28 score of \> 5.1.
Time frame: 0 to 24 weeks
Mean Change in Modified Total Sharp Score at Week 24
The modified total Sharp score method was used to evaluate radiographs of hands/wrists for erosions (ERO) and joint space narrowing (JSN). The total modified Sharp score ranges from 0 (no radiographic damage) to 200 (worst possible radiographic damage) and is the sum of the normalized ERO score (range 0-100) and the normalized JSN score (range 0-100). Higher scores indicated more damage.
Time frame: Baseline, 24 weeks
Adverse Events (AE) Overview
Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 48/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBRA99/NCT00583557).
Time frame: Up to 56 weeks
| Milestone | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Started | 69 | 72 | 71 | 71 |
| Completed | 59 | 66 | 63 | 60 |
| Not completed | 10 | 6 | 8 | 11 |
| Withdrew: Adverse event | 2 | 3 | 4 | 4 |
| Withdrew: Lack of efficacy | 3 | 1 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 1 | 1 | 5 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 |
| Milestone | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Started | 0 | 11 | 8 | 218 |
| Completed | 0 | 11 | 7 | 178 |
| Not completed | 0 | 0 | 1 | 40 |
| Withdrew: Adverse event | 0 | 0 | 0 | 7 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 17 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 12 |
| Withdrew: Lack of compliance | 0 | 0 | 1 | 2 |
An ACR20 response is defined as having at least a 20% improvement in tender and swollen joints as well as a 20% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate \[ESR\]).
| percentage of participants | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Percentage of Patients With ACR20 (American College of Rheumatology) Response at Week 24, Based on Erythrocyte Sedimentation Rate (ESR) | 15.9 | 34.7 | 25.4 | 28.2 |
An ACR50 response is defined as having at least a 50% improvement in tender and swollen joints as well as a 50% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate \[ESR\]).
| percentage of participants | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Percentage of Patients With an ACR50 Response at Week 24, Based on ESR | 4.3 | 9.7 | 8.5 | 14.1 |
An ACR70 response is defined as having at least a 70% improvement in tender and swollen joints as well as a 70% improvement in 3 of 5 other criteria (patient assessment, physician assessment, pain scale, disability/functional questionnaire, and acute phase reactant value based on erythrocyte sedimentation rate \[ESR\]).
| percentage of participants | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Percentage of Patients With an ACR70 Response at Week 24, Based on ESR | 2.9 | 5.6 | 1.4 | 2.8 |
The time to first ACR20 response (based on ESR) is defined as the time from the first dose to the first visit at which a patient first exhibited an ACR20 response, which may or may not have been sustained through Week 24.
| days | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Time to First ACR20 Response, Based on ESR | 112 (84 to NA) | 109 (60 to 168) | 112 (49 to NA) | 111 (57 to NA) |
Measure not posted because time to ACR50 response was unable to be determined due to the small number of patients achieving an ACR50 response in the study.
Results for this outcome have not been posted.
Measure not posted because time to ACR70 response was unable to be determined due to the small number of patients achieving an ACR70 response in the study.
Results for this outcome have not been posted.
DAS is a composite index of a patient's level of RA disease activity. DAS28 is an abbreviated version of DAS, using a subset of 28 joints in the assessment, calculated based on 4 variables: 1) number of tender joints out of a total of 28 joints, 2) number of swollen joints out of a total of 28 joints, 3) ESR, 4) patient's global assessment of disease activity based on a 100-mm visual analog scale. The calculation provides a number on a scale from 0 to 10 (\>5.1=active disease; \<3.2=well controlled disease; \<2.6=remission). Change from baseline \>1.2 = good response and ≤0.6 = non-response.
| scores on a scale | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Mean Change in Disease Activity Score 28 (DAS28) at Week 24 | -0.9 ± 0.15 | -1.3 ± 0.18 | -0.9 ± 0.14 | -1.5 ± 0.15 |
DAS28 response is defined as the time from the first dose to the first time at which a patient exhibited a "good" or a "moderate" improvement in RA disease activity, based on DAS28 improvements compared to baseline. Good response was defined as \>1.2 change from baseline and DAS28 score ≤ 3.2. No response was defined as ≤ 0.6 change from baseline in DAS28 score or change between ≤ 1.2 and \> 0.6 with a DAS28 score of \> 5.1.
| days | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Time to First DAS28 Response | 111 (56 to 168) | 82 (51 to 114) | 84 (33 to 168) | 57 (30 to 111) |
The modified total Sharp score method was used to evaluate radiographs of hands/wrists for erosions (ERO) and joint space narrowing (JSN). The total modified Sharp score ranges from 0 (no radiographic damage) to 200 (worst possible radiographic damage) and is the sum of the normalized ERO score (range 0-100) and the normalized JSN score (range 0-100). Higher scores indicated more damage.
| scores on a scale | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC |
|---|---|---|---|---|
| Mean Change in Modified Total Sharp Score at Week 24 | 0.7 ± 0.2 | 0.3 ± 0.2 | 0.3 ± 0.2 | 0.6 ± 0.2 |
Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 48/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBRA99/NCT00583557).
| percentage of participants | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC | Open-label Extension Period: All Active |
|---|---|---|---|---|---|
| Percent of patients with at least 1 AE | 89.9 | 84.7 | 90.1 | 93.0 | 91.6 |
| Percent of patients with at least 1 SAE | 7.2 | 6.9 | 7.0 | 8.5 | 11.0 |
| Percent of patients with an AE resulting in death | 1.5 | 0 | 0 | 1.4 | 0 |
Collected over Up to 56 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Plus SOC | — | 5/69 (7.2%) | 50/69 (72.5%) |
| Belimumab 1 mg/kg Plus SOC | — | 5/72 (6.9%) | 47/72 (65.3%) |
| Belimumab 4 mg/kg Plus SOC | — | 5/71 (7%) | 48/71 (67.6%) |
| Belimumab 10 mg/kg Plus SOC | — | 6/71 (8.5%) | 54/71 (76.1%) |
| Open-label Extension Period: All Active | — | 26/237 (11%) | 165/237 (69.6%) |
| Event | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC | Open-label Extension Period: All Active |
|---|---|---|---|---|---|
| Cardiac arrestCardiac disorders | 1/69 | 0/72 | 0/71 | 0/71 | 0/237 |
| Myocardial infarctionCardiac disorders | 1/69 | 0/72 | 1/71 | 0/71 | 0/237 |
| Non-cardiac chest painGeneral disorders | 1/69 | 0/72 | 1/71 | 0/71 | 0/237 |
| CholecystitisHepatobiliary disorders | 1/69 | 0/72 | 0/71 | 0/71 | 0/237 |
| CholelithiasisHepatobiliary disorders | 1/69 | 0/72 | 0/71 | 1/71 | 0/237 |
| Viral infectionInfections and infestations | 1/69 | 0/72 | 0/71 | 0/71 | 0/237 |
| ArthropathyMusculoskeletal and connective tissue disorders | 1/69 | 0/72 | 0/71 | 0/71 | 0/237 |
| Ovarian cystReproductive system and breast disorders | 1/69 | 0/72 | 0/71 | 0/71 | 0/237 |
| AnaemiaBlood and lymphatic system disorders | 0/69 | 0/72 | 0/71 | 1/71 | 1/237 |
| Acute coronary syndromeCardiac disorders | 0/69 | 0/72 | 1/71 | 0/71 | 0/237 |
| Event | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC | Open-label Extension Period: All Active |
|---|---|---|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 16/69 | 21/72 | 15/71 | 24/71 | 75/237 |
| Upper respiratory tract infectionInfections and infestations | 9/69 | 6/72 | 9/71 | 10/71 | 38/237 |
| Joint swellingMusculoskeletal and connective tissue disorders | 3/69 | 4/72 | 6/71 | 11/71 | 21/237 |
| Oedema peripheralGeneral disorders | 4/69 | 3/72 | 9/71 | 3/71 | 25/237 |
| DiarrhoeaGastrointestinal disorders | 6/69 | 6/72 | 2/71 | 8/71 | 15/237 |
| Urinary tract infectionInfections and infestations | 6/69 | 8/72 | 8/71 | 4/71 | 17/237 |
| HeadacheNervous system disorders | 4/69 | 7/72 | 5/71 | 8/71 | 12/237 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/69 | 1/72 | 3/71 | 8/71 | 12/237 |
| FatigueGeneral disorders | 4/69 | 5/72 | 6/71 | 7/71 | 18/237 |
| SinusitisInfections and infestations | 2/69 | 3/72 | 7/71 | 3/71 | 13/237 |
| Age Continuous(years) | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC | Total |
|---|---|---|---|---|---|
| Mean | 50.7 ± 8.8 | 50.6 ± 8.3 | 50.7 ± 10.2 | 49.5 ± 9.3 | 50.4 ± 9.1 |
| Sex: Female, Male(Participants) | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC | Total |
|---|---|---|---|---|---|
| Female | 56 | 56 | 60 | 54 | 226 |
| Male | 13 | 16 | 11 | 17 | 57 |
| Region of Enrollment(participants) | Placebo Plus SOC | Belimumab 1 mg/kg Plus SOC | Belimumab 4 mg/kg Plus SOC | Belimumab 10 mg/kg Plus SOC | Total |
|---|---|---|---|---|---|
| United States | 55 | 61 | 59 | 59 | 234 |
| Poland | 14 | 11 | 12 | 12 | 49 |
The record gives a start of Dec 2003, a primary completion of Jan 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2012, 7 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab